株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
年間契約型情報サービス

Autoimmune Drug Focus (ADF)

Autoimmune Drug Focus

発行 Fitch Solutions, Inc. 商品コード 26341
出版日 年12回 年間契約型情報サービス ページ情報 英文 24 Pages
価格
本日の銀行送金レート: 1USD=109.41円で換算しております。
Back to Top
Autoimmune Drug Focus (ADF) Autoimmune Drug Focus
出版日: 年12回 年間契約型情報サービス ページ情報: 英文 24 Pages
担当者のコメント
年間契約型の定期配信サービスです。最新のバックイシューをまずは無料でお送りいたしますので、サンプル依頼ボタンよりお問い合わせください。
概要

世界の人口の約 4% が自己免疫疾患で苦しんでおり、罹患率は上昇傾向にあり、毎年、自己免疫疾患の原因を特定するための研究に何百万ドルもの費用が投資されています。

医療機器、医薬品などに関する情報提供で世界的に高い評価を得ております英国の調査会社Espicom Business Intelligenceは、自己免疫系疾患治療薬市場の最新情報に関する英文ニューズレター "Autoimmune Drug Focus (ADF)" をご提供しております。

当ニューズレターでは、自己免疫系疾患治療薬の開発状況、企業や医薬品の概要や今後実施されるコンファレンスに関する情報など、市場に関する最新情報をご提供しております。

<構成>

  • 糖尿病
  • 炎症性腸疾患(大腸クローン病および潰瘍性大腸炎を中心とする)
  • 多発性硬化症
  • 筋骨格疾病(慢性関節リューマチ、ループスなどを中心とする)
  • 乾癬
  • 開発状況
  • コンファレンスリスト
目次
Product Code: 1746-1243

BMI View: EU approval puts Cosentyx on course to achieve blockbuster status, with US approval also anticipated early in 2015. Novartis' drug has already shown superiority over its main competition in the lucrative adult plaque psoriasis market. As many as 50% of patients are unhappy with their treatments; if Cosentyx can overcome this hurdle it will emerge as a clear winner.

Table of Contents

  • Novartis In Pole Position With Cosentyx' EU Approval For Plaque Psoriasis Diabetes
  • Agreements
  • Lilly/Adocia To Co-Develop BioChaperone Technology-Based Ultra-Rapid Insulin
  • MannKind Earns Milestone Payment From Sanofi
  • Product Updates
  • Tresiba Gains CHMP Positive Opinion For Expanded Use
  • Additional Patent Protection Underlines Diamyd's Potential
  • R&D
  • Positive Preliminary Results Reported From Biodel's BIOD-531 Phase IIa Study In Diabetes
  • Adocia Begins Phase Ib Trial To Evaluate Post-Meal Effect Of BioChaperone Lispro Inflammatory Bowel Diseases
  • Agreements
  • TxCell/Ferring Collaborate With Trizell For Development Of Ovasave
  • Janssen/Vedanta Sign Licensing Deal For Microbiome Candidate In IBD
  • Product Updates
  • TxCell Secures Funds For Ovasave Development In Refractory Crohn's Disease
  • R&D
  • Galapagos Initiates Phase II Trial Of GLPG1205 In UC
  • Positive Results Reported From Arena's APD334 Phase Ib Trial In Autoimmune Diseases
  • TiGenix Granted European Patent Covering Adipose-Derived Stem Cell Compositions Multiple Sclerosis
  • Product Updates
  • Takeda Submits Glatiramer Acetate NDA In Japan For Relapse Prevention Of MS
  • Supreme Court Ruling Will Boost Teva's Copaxone Revenues
  • R&D
  • First Patient Treated In Mapi's Phase IIa Trial Of GA Depot For RRMS Musculoskeletal Disorders
  • Arthritis - Agreements
  • Torrent And Reliance Life Sciences Enter India Biosimilars Agreement
  • Product Updates
  • Health Canada Approves Actemra For Early RA
  • EMA Accepts Samsung Bioepis' Etanercept Biosimilar For Review
  • R&D
  • NSAID Market Set To Welcome Encapsulated Equivalents
  • Can-Fite Completes Design Of CF101 Phase III RA Study
  • Duvelisib Phase II RA Study Misses Primary Endpoint
  • Other Musculoskeletal Disorders - R&D
  • Premier Files Initial FDA Submission For Fibromyalgia Treatment Psoriasis
  • Product Updates
  • Novartis' Cosentyx Approved In Japan For Psoriasis Vulgaris/PsA
  • LEO Submits NDA For Calcipotriene+Betamethasone Aerosol Foam In Plaque Psoriasis
  • Perrigo Launches Clobetasol Spray In US
  • EU Approval Sets Stage For Otezla's Blockbuster Future
  • Novartis' Cosentyx Gains FDA Approval For Plaque Psoriasis
  • R&D
  • Kadmon Initiates KD025 Phase II Trial In Psoriasis
  • Cimzia Phase III Programme Initiated In Psoriasis General Developments
  • Agreements
  • OrImmune/Nanjing BioSciKin Enter China Anti-CD3 Antibody Collaboration
  • Tiziana Licenses Foralumab From Novimmune
  • EpiVax/Novozymes Enter Tregitope Autoimmune Agreement
  • Isis/Janssen To Co-Develop Antisense Drugs For GI Tract Autoimmune Disorders
  • Evotec/Padlock Extend Collaboration
  • Genomic Data Partnerships Will Bolster Drug Development
  • Product Updates
  • GSK Submits Promacta sNDA To FDA
  • EU Approval For Ofev In IPF Will Create A Blockbuster In An Intense Market
  • R&D
  • ImmuPharma/Simbec-Orion Collaborate To Begin Lupuzor Phase III Study In SLE Corporate Activity
  • Padlock Raises Funds To Advance PAD-Directed Therapeutics
  • Aldeyra Raises Funds Via Private Placement Conference Listings
Back to Top